This study evaluates the efficacy of the HIFU for the treatment of breast fibroadenoma with the FastScan version using assessment of patient experience and adverse event reporting.
Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area. In a previous european feasibility study performed at 4 sites (France and Bulgaria), 51 fibroadenomas in 42 patients were treated. The HIFU treatment was well tolerated and showed efficacy (mean volume reduction of 72.5% +/-16.7 at 12 months follow-up.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
HIFU Under ultrasound guidance
University Hospital of Endocrinology USBALE
Sofia, Bulgaria
Number of participants with adverse events
Time frame: 1 day post treatment
Number of participants with adverse events
Time frame: 3 days post treatment
Number of participants with adverse events
Time frame: 7 days post treatment
Change from Baseline volume of the fibroadenoma at 6 months
Time frame: 6 months post treament
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 1 day
Time frame: 1 day post treatment
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 3 days
Time frame: 3 days post treatment
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 7 days
Time frame: 7 days post treatment
Patient satisfaction questionnaire
Time frame: 6 months post treatment
Number of participants with absence of palpable lesion
Time frame: 3 months post treatment
Number of participants with absence of palpable lesion
Time frame: 6 months post treatment
Patient Cosmetic evaluation as measured by questionnaire
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 months post treatment
Investigator rated evaluation of the device
Time frame: Post treatment Day 0
Change from Baseline gland vascularization at 3 months
Time frame: 3 months post treatment
Change from Baseline gland vascularization at 6 months
Time frame: 6 months post treatment